

## APPENDICES

Cumulative indices for 2006

### Author Index

- Abdollahi M  
3(1), 113–117  
3(1), 119–123
- Acebey NE  
3(2), 255–257
- Afshari M  
3(1), 119–123
- Ahmed M  
3(1), 1–3
- Aidiētis A  
3(1), 125–138
- Akman A  
3(1), 139–151
- Al-Mosawi AJ  
3(2), 264–272  
3(2), 299–321
- Alpsoy E  
3(1), 139–151
- Antoniou KM  
3(1), 163–174  
3(2), 247–250
- Astanehi-Asghari F  
3(1), 119–123
- Baeten D  
3(2), 191–200
- Baiaty A  
3(1), 113–117
- Beaulieu J  
3(1), 69–78
- Beck M  
3(1), 9–17
- Bertoni E  
3(2), 201–214
- Born L  
3(1), 153–162
- Bouros D  
3(1), 163–174
- Chesney RW  
3(2), 183–185
- De Francesco V  
3(2), 251–254
- de la Rosette J JMCH  
3(2), 237–246
- Del Grande JC  
3(2), 255–257
- DiBaise JK  
3(1), 55–67
- Dieter RS  
3(1), 1–3
- Dupont C  
3(1), 69–78
- Ellegard EK  
3(1), 89–92
- Ellegard LH  
3(1), 89–92
- Ghameinezhad S  
3(1), 113–117
- Hammerbeck U  
3(2), 273–289
- Hassan C  
3(2), 251–254
- Hehmat R  
3(1), 119–123
- Herbella FAM  
3(2), 255–257
- Hosseinnezhad A  
3(1), 119–123
- Hull D  
3(2), 259–264
- Hunt MA  
3(1), 97–112
- Ierardi E  
3(2), 251–254
- Ikram S  
3(1), 1–3
- Jahke K  
3(1), 97–112
- Kraemer DF  
3(1), 97–112
- Larijani B  
3(1), 119–123
- Lebert F  
3(1), 93–96
- Lemieux P  
3(1), 69–78
- Makela P  
3(2), 273–289
- Malekirad AA  
3(1), 113–117
- Marinskis G  
3(1), 125–138
- Maron L  
3(1), 97–112
- Michel MC  
3(2), 237–246
- Mohammadirad A  
3(1), 113–117  
3(1), 119–123
- Mojtahedi A  
3(1), 119–123
- Morini S  
3(2), 251–254
- Muldoon LL  
3(1), 97–112
- Nanjundappa A  
3(1), 1–3
- Neuwelt EA  
3(1), 97–112
- Nicolau DP  
3(2), 259–264
- Nightingale CH  
3(2), 259–264
- Orbay P  
3(1), 97–112
- Pacanowski Jr J  
3(1), 1–3
- Panella C  
3(2), 251–254
- Patters AB  
3(2), 183–185
- Phillips SD  
3(1), 153–162
- Ranjbar A  
3(1), 113–117
- Rezaie A  
3(1), 119–123
- Rusconi S  
3(1), 79–88
- Rushton DN  
3(2), 273–289
- Salvadori M  
3(2), 201–214
- Sand PK  
3(2), 215–226
- Smithard DG  
3(2), 291–298
- Sung J JY  
3(2), 227–236
- Turgay A  
3(1), 19–38
- Tyson RM  
3(1), 97–112
- Tzouveleakis A  
3(1), 163–174
- van Dijk MM  
3(2), 237–246
- Vazquez JA  
3(1), 39–54
- Vigano O  
3(1), 79–88
- Wong G L-H  
3(2), 227–236
- Xuan D  
3(2), 259–264
- Yanagita ET  
3(2), 255–257
- Zamani H  
3(1), 113–117
- Zinga D  
3(1), 153–162
- Zullo A  
3(2), 251–254
- Acacia gum  
3(2), 183–185  
3(2), 265–272
- Acetylcholine  
3(2), 291–298
- Acetylcholinesterase  
3(1), 93–96
- Acute anterior uveitis  
3(2), 191–200
- Adderal XR® (see psychostimulants)
- Adriamycin  
3(1), 97–112
- AG-001859  
3(1), 79–88
- Aldosterone receptor blockers  
3(1), 125–138
- Alteplase  
3(1), 163–174
- Aluminium acetate  
3(1), 139–151
- Amiodarone  
3(1), 125–138
- Amlexanox  
3(1), 139–151
- Amoxicillin  
3(2), 251–254
- Amphetamine  
3(1), 19–38
- Amphotericin B  
3(1), 39–54
- Amprenavir (APV)  
3(1), 79–88
- Angiotensin-converting enzyme inhibitors  
3(1), 125–138
- Anidulafungin  
3(1), 39–54
- Ankylosing spondylitis  
3(2), 191–200
- Anterolateral partial fundoplication (see Heller–Pinotti procedure)
- Anthracycline  
3(1), 97–112
- Antidepressants  
3(1), 19–38
- Anti-HIV-1  
3(1), 79–88
- Antihypertensives  
3(1), 19–38
- Antimuscarinic drugs  
3(2), 215–226
- Antipseudomonal penicillins  
3(1), 163–174
- Antipseudomonal quinolones  
3(1), 163–174
- Antitumor necrosis factor- $\alpha$   
3(1), 139–151
- Arteriovenous malformation  
3(2), 273–289

### Compound Index

- 2,4,6-tripyridyl-S-triazine  
3(1), 113–117
- 2-thiobarbituric acid  
3(1), 113–117
- 5-fluorouracil  
3(1), 97–112
- <sup>99m</sup>Tc-glucoheptonate  
3(1), 97–112
- <sup>99m</sup>Tc-albumin  
3(1), 97–112
- $\alpha$ 1-adrenergic receptor  
3(2), 237–246

- Arthritis associated with inflammatory bowel disease  
3(2), 191–200
- Aspiration  
3(2), 291–298
- Aspirin  
3(2), 227–236
- Atazanavir  
3(1), 79–88
- Atomoxetine hydrochloride  
3(1), 19–38
- Atropine  
3(2), 215–226
- Azathioprine  
3(1), 139–151  
3(2), 201–214
- Azoles  
3(1), 39–54
- Aztreonam  
3(1), 163–174
- $\beta$ -blocker  
3(1), 125–138  
3(1), 119–123
- $\beta$ -lactoglobulin  
3(1), 69–78
- $\beta$ -lactotensin  
3(1), 69–78
- Bayesian estimation  
3(2), 259–264
- Benign prostatic hyperplasia  
3(2), 237–246
- Benzatin penicillin  
3(1), 139–151
- Benzodiazepine  
3(2), 291–298
- Benzydamine  
3(1), 139–151
- BILA-2185 BS  
3(1), 79–88
- Bovine serum albumin  
3(1), 69–78
- BR96-DOX  
3(1), 97–112
- Bupropion  
3(1), 19–38  
3(1), 153–162
- Burow's solution  
3(1), 139–151
- C-reactive protein  
3(2), 191–200
- Capecitabine  
3(1), 97–112
- Carbamazepine  
3(1), 39–54
- Carbapenems  
3(1), 163–174
- Carboplatin  
3(1), 97–112
- 3(1), 139–112
- Cardiomyotomy  
3(2), 255–257
- Cardiovascular comorbidity  
3(2), 237–246
- Carvedilol  
3(1), 119–123
- Caspofungin  
3(1), 39–54
- Catapres® (see clonidine)
- Cephalosporins  
3(1), 163–174
- Chagas' disease  
3(2), 255–257
- Chagasic achalasia  
3(2), 255–257
- Chlorambucil  
3(1), 139–151
- Chlorhexidine  
3(1), 139–151
- Cholinergic acetyltransferase  
3(1), 93–96
- Cholinesterase inhibitors  
3(1), 93–96
- Chronic obstructive pulmonary disorder  
3(2), 247–250
- Cinnamomum zeylanicum*  
3(1), 113–117
- Ciprofloxacin  
3(1), 163–174
- Cilomilast  
3(2), 247–250
- Cisplatin  
3(1), 97–112
- Citalopram  
3(1), 153–162
- Clindamycin  
3(1), 163–174
- Clonazepam  
3(1), 153–162
- Clonidine  
3(1), 19–38
- Clopidogrel  
3(2), 227–236
- Colchicine  
3(1), 139–151
- Concerta® (see psychostimulants)
- Corticosteroids  
3(1), 139–151
- Crohn's disease  
3(2), 191–200
- Cyclooxygenase  
3(2), 227–236
- Cyclophosphamide  
3(1), 97–112
- 3(1), 139–151
- Cyclosporin A  
3(1), 139–151  
3(2), 201–214  
3(2), 259–264
- Cyclosporine  
3(1), 39–54  
3(1), 139–151  
3(2), 201–214
- Dapsone  
3(1), 139–151
- Desipramine  
3(1), 19–38
- Dexamethasone  
3(1), 39–54  
3(1), 69–78
- Dexedrine® (see dextroampheteramine)
- Dextroampheteramine  
3(1), 19–38
- Dialysis  
3(2), 265–272
- Diclofenac  
3(1), 139–151
- Disability  
3(2), 273–289
- Dithiobis-2-nitrobenzoic acid  
3(1), 113–117
- DMP 450® (see mozenavir)
- Dopamine  
3(2), 291–298
- Doxorubicin  
3(1), 97–112
- Docetaxel  
3(1), 97–112
- Dx Spansule® (see psychostimulants)
- Dyspepsia  
3(2), 251–254  
3(2), 227–236
- Echinocardins  
3(1), 39–54
- End-stage renal failure  
3(2), 265–272
- Esomeprazole  
3(2), 227–236
- Esophageal manometry  
3(2), 255–257
- Etanercept  
3(1), 139–151
- Etoposide  
3(1), 97–112
- Etoposide phosphate  
3(1), 97–112
- First-generation HIV-1 protease inhibitors  
3(1), 79–88
- Fluoxetine  
3(1), 19–38  
3(1), 153–162
- Fluvoxamine  
3(1), 93–96  
3(1), 153–162
- Focalin® (see psychostimulants)
- Galsulfase  
3(1), 9–17
- Gastric carcinogenesis  
3(2), 251–254
- Gemcitabine  
3(1), 97–112
- Glomerular filtration rate  
3(2), 183–185
- Glutamine  
3(1), 55–67
- Glutathione  
3(1), 113–117
- Glycyl-leucyl-phenylalanine  
3(1), 69–78
- Guanfacine  
3(1), 19–38
- GW640385  
3(1), 79–88
- Helicobacter pylori  
3(2), 251–254  
3(2), 227–236
- Heller-Pinotti procedure  
3(2), 255–257
- Hemodialysis  
3(2), 265–272
- Herstatin  
3(1), 97–112
- Herstatin  
3(1), 97–112
- Hexetidinie  
3(1), 139–151
- IFN-2 $\alpha$   
3(1), 139–151
- IFN- $\alpha$   
3(1), 139–151
- Imipramine  
3(1), 19–38
- Immunoglobulin  
3(1), 69–78
- Indinavir  
3(1), 79–88  
3(2), 191–200
- Infliximab  
3(1), 139–151
- Inhaled corticosteroids  
3(2), 247–250
- Inosine monophosphate dehydrogenase  
3(2), 201–214
- Interferon  
3(1), 139–151
- Intermittent peritoneal dialysis  
3(2), 265–272

## APPENDICES

Intravenous aminopenicillin 3(1), 163–174	Nefazodone 3(1), 153–162	3(2), 251–254	3(1), 19–38
Itraconazole 3(1), 39–54	Nelfinavir 3(1), 79–88	Piracetam 3(1), 93–96	3(1), 153–162
Kidney transplant 3(2), 259–264	Neoral® (see Cyclosporin A)	PL100 3(1), 79–88	Serotonin 3(2), 291–298
Lactoferrin 3(1), 69–78	Neuromodulator 3(2), 291–298	Pneumonia 3(2), 291–298	Serotonin selective re-uptake inhibitors 3(1), 93–96
Lapatinib 3(1), 97–112	Neuropeptide 3(2), 291–298	Population pharmacokinetics 3(2), 259–264	Sertraline 3(1), 153–162
Laronidase 3(1), 9–17	Nitric oxide 3(2), 183–185	Posaconazole 3(1), 39–54	Several second-generation protease inhibitors 3(1), 79–88
Levamisole 3(1), 139–151	Nucleoside 3(1), 79–88	Postoperative dysphagia 3(2), 255–257	SGN-15 3(1), 97–112
Levofloxacin 3(2), 251–254	Non-nucleoside inhibitors of reverse transcriptase 3(1), 79–88	Prednisolone 3(1), 139–151 3(1), 97–112	Silver nitrate 3(1), 139–151
Lidocaine 3(1), 139–151	NSAID 3(2), 191–200 3(2), 227–236	Preoperative manometry 3(2), 255–257	Sirolimus 3(1), 1–3
Liposomal doxorubicin 3(1), 97–112	Omeprazole 3(2), 227–236	Proton pump inhibitor 3(2), 227–236	Sodium thiosulfate 3(1), 97–112
Listerine 3(1), 139–151	Ondansetron 3(1), 97–112	Psoriatic arthritis 3(2), 191–200	Somatropin 3(1), 55–67
Lopinavir 3(1), 79–88	Orabase 3(1), 139–151	Psychostimulants 3(1), 19–38	Sotalol 3(1), 125–138
Lorazepam 3(1), 153–162	Oral-controlled absorption system 3(2), 237–246	Rabeprazole 3(2), 251–254	Speech and language therapy 3(2), 273–289
Luciferase 3(1), 97–112	Ovalbumin 3(1), 69–78	Reactive arthritis 3(2), 191–200	SPI-70095 3(1), 79–88
Malonedialdehyde 3(1), 113–117	Overactive bladder 3(2), 215–226	Recombinant human growth hormone 3(1), 55–67	Statins 3(1), 125–138
Mannitol 3(1), 97–112	Oxaliplatin 3(1), 97–112	Rehabilitation 3(2), 273–289	Strattera® (see atomoxetine hydrochloride)
Mepivacaine 3(1), 139–151	Oxazolone 3(1), 69–78	Renal transplant 3(2), 259–264	Streptodornase 3(1), 163–174
Metadate CD® (see psychostimulants)	Paclitaxel 3(1), 1–3 3(1), 97–112	Renal-replacement therapy 3(2), 265–272 3(2), 183–185	Streptodornase-a 3(1), 163–174
Methotrexate 3(1), 97–112 3(1), 139–151 3(2), 191–200	Paroxetine 3(1), 19–38	Resistant-Repellent™ (see SPI-70095)	Streptokinase 3(1), 163–174
Methylin ER® (see psychostimulants)	3(1), 93–96	Rheumatoid arthritis 3(2), 191–200	Striatal-nigral pathway 3(2), 291–298
Methylphenidate 3(1), 19–38	3(1), 153–162	Rifampin 3(1), 39–54	Stroke 3(2), 273–289
Methylphenidate SR® (see psychostimulants)	Patent foramen ovale 3(2), 273–289	Ritalin LA® (see psychostimulants)	3(2), 291–298
Methylprednisolone 3(1), 139–151	Paxil® (see paroxetine)	Ritalin SR® (see psychostimulants)	Substance P 3(2), 291–298
Methylxantines 3(2), 247–250	Penicillins 3(1), 163–174	Ritalin® (see methylphenidate)	Sucalfate 3(1), 139–151
Methypatch® (see psychostimulants)	Peptic ulcer 3(2), 251–254	Ritalin® (see methylphenidate)	Superparamagnetic iron oxide nanoparticles 3(1), 97–112
Micafungin 3(1), 39–54	Peristalsis 3(2), 227–236	Ritonavir 3(1), 79–88	Swallowing 3(2), 291–298
Mozenavir 3(1), 79–88	Pharmacokinetic profile 3(2), 255–257	Roflumilast 3(2), 247–250	Systemic lupus erythematosus 3(2), 273–289
Mycophenolate mofetil 3(2), 201–214	Phenobarbital 3(1), 153–162	Sequential therapy 3(2), 251–254	Tacrolimus 3(1), 39–54
Mycophenolate sodium 3(2), 201–214	Phosphodiesterase 4 inhibitors 3(2), 247–250	Saquinavir 3(1), 79–88	Tamoxifen 3(1), 19–38
Mycophenolic acid 3(2), 201–214	Pilot study	Second-generation cephalosporin 3(1), 163–174	
		Selective norepinephrine reuptake inhibitor	

Tamsulosin	3(2), 237–246	Thrombotic thrombocytopenic purpura	3(2), 273–289	Trazodone	3(1), 93–96	Urge urinary incontinence	3(2), 215–226
Taxotere	3(1), 97–112	Tipranavir	3(1), 79–88	Triamcinolone acetonide	3(1), 139–151	Vancomycin	3(1), 163–174
Tenex® (see guanfacine)		TMC 114	3(1), 79–88	Trichloroacetic acid	3(1), 113–117	Venlafaxine	3(1), 153–162
Tetracaine	3(1), 139–151	TMC 126	3(1), 79–88	Tricyclic antidepressants	3(1), 19–38	Venlafaxine	3(1), 19–38
Tetracycline	3(1), 139–151	Tofranil® (see imipramine)		Tricyclics	3(1), 153–162	Verapamil	3(1), 125–138
Tetraethoxypropane	3(1), 113–117	Topoisomerase I agents	3(1), 97–112	Tris base	3(1), 113–117	Vincristine	3(1), 97–112
Tetrahydrofuran	3(1), 79–88	Topoisomerase II agents	3(1), 97–112	Trospium	3(2), 215–226	Vinorelbine	3(1), 97–112
Thalidomide	3(1), 139–151	Transient ischemic attack	3(2), 273–289	Tyr-gly-gly	3(1), 69–78	Voriconazole	3(1), 39–54
Third-generation cephalosporins	3(1), 163–174	Trastuzumab	3(1), 97–112	Undifferentiated spondyloarthropathy	3(2), 191–200	Welbutrin® (see bupropion)	
		Trazodone	3(1), 153–162	Uremia	3(2), 265–272	Xanthan gum	3(2), 183–185